Back to search
FDAFDA · Food and drugs·Recall number D-1545-2020

Losartan Potassium Tablets USP, 50 mg, 90 count bottles, Rx only, Manufactured for: Camber Pharmaceuticals, Inc., Piscataway, NJ by Hetero Labs, Limited, Mahabubragar, India

Published September 2, 2020 · Recall initiated: August 6, 2020

Summary

FDA records drug Class II recall D-1545-2020, published September 2, 2020 and initiated August 6, 2020. Recalling firm: Hetero Labs Limited (Unit V); Status: Terminated; Reported quantity: 43,512 bottles; Lot: Batch # LOA19357A, exp. date 09/2021. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Tablet/Capsule Specification; complaint of bulging tablet

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Hetero Labs Limited (Unit V)
Distributor
Product was distributed to major wholesalers/distributors throughout the United States.
Lot
Batch # LOA19357A, exp. date 09/2021
Risk classification
Class II
Area (FDA)
drug
Country
India

Related recalls

Questions about this recall

Was Losartan Potassium Tablets USP, 50 mg, 90 count bottles, Rx only, Manufactured for: Camber Pharmaceuticals, Inc., Piscataway, NJ by Hetero Labs, Limited, Mahabubragar, India recalled?

Yes. FDA published recall D-1545-2020 on September 2, 2020. Reported hazard: Failed Tablet/Capsule Specification; complaint of bulging tablet

What should I do if I have this product?

Voluntary: Firm initiated · Letter